New drug combo aims to stop deadly liver Cancer's return
NCT ID NCT04639180
Summary
This study is testing whether a combination of two drugs, camrelizumab and rivoceranib, can help prevent liver cancer from returning in patients who are at high risk of recurrence after their initial tumor has been surgically removed or destroyed. The trial will compare the drug combination against active monitoring (no additional treatment) to see which approach better keeps the cancer from coming back. It involves nearly 700 patients who have had successful initial treatment but remain at high risk for the cancer's return.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Guangxi Medical University Affiliated Tumor Hospital
Nanjin, Guangzhou, China
-
Guizhou Cancer Hospital
Guiyang, Guizhou, China
-
Renji Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China
-
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China
-
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China
Conditions
Explore the condition pages connected to this study.